Novosibirsk: Viral vector and mRNA vaccines, including Russia’s Sputnik V COVID-19 Vaccine, proves 90 per cent protection against the new Delta variant of the coronavirus, Head of the Novosibirsk State University’s Laboratory and corresponding member of the Russian Academy of Sciences (RAS) Sergey Netesov told Sputnik.
“According to data from the UK, the US and other countries, mRNA and vector vaccines, including our Sputnik V, protect against it [the Delta variant], albeit to a lesser extent, but they do protect against it. They offered 95 per cent protection against the initial strain and now they give 90% protection against the ‘delta’ variant,” Sergey Netesov said.
Netesov also added that the COVID-19 vaccines already developed should be used as they are pretty effective as well.
Vladimir Gushchin, the head of the population variability mechanisms laboratory of the Gamaleya research center that developed the Sputnik V Covid vaccine, had said during the end of June that the Russian jabs guarantee nearly 100 per cent protection against fatal and severe cases of Coronavirus caused by the Delta strain.
During August 2020, Russia became the first nation in the world to register a vaccine against COVID-19, dubbed Sputnik V.
Sputnik V, which also goes by the name of Gam-COVID-Vac, uses two different engineered adenoviruses (rAd26 and rAd5 for the first and second jabs, respectively) to deliver the genetic code for the spike protein of the SARS-CoV-2 into the cells of humans. Usually, adenoviruses cause only mild illness in humans and by opting for two different delivery mechanisms, instead of just using one engineered adenovirus like the Oxford-AstraZeneca and Johnson & Johnson vaccines do, the Russian developers were aiming to increase the efficacy of the vaccine.
As per an interim study from a trial published in The Lancet medical journal, the Sputnik V Covid vaccine has 91.6 per cent efficacy. Furthermore, the Gamaleya National Research Center of Epidemiology and Microbiology, which manufactured Sputnik V, and the Russian Direct Investment Fund (RDIF) have reported that Sputnik V has 97.6 per cent efficacy.
Meanwhile, there have been no reports of rare blood-clotting conditions in humans vaccinated with Sputnik V from Russian health authorities or from over 60 countries now using Sputnik V, unlike Oxford-AstraZeneca and Johnson & Johnson vaccines.